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Use of antiretroviral therapy in households and risk of HIV 
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Summary
Background Studies of HIV-serodiscordant couples in stable sexual relationships have provided convincing evidence 
that antiretroviral therapy can prevent the transmission of HIV. We aimed to quantify the preventive eﬀ ect of a public-
sector HIV treatment and care programme based in a community with poor knowledge and disclosure of HIV status, 
frequent migration, late marriage, and multiple partnerships. Speciﬁ cally, we assessed whether an individual’s hazard 
of HIV acquisition was associated with antiretroviral therapy coverage among household members of the opposite sex.
Methods In this prospective cohort study, we linked patients’ records from a public-sector HIV treatment programme in 
rural KwaZulu-Natal, South Africa, with population-based HIV surveillance data collected between 2004 and 2012. We 
used information about coresidence to construct estimates of HIV prevalence and antiretroviral therapy coverage for 
each household. We then regressed the time to HIV seroconversion for 14 505 individuals, who were HIV-uninfected at 
baseline and individually followed up over time regarding their HIV status, on opposite-sex household antiretroviral 
therapy coverage, controlling for household HIV prevalence and a range of other potential confounders.
Findings 2037 individual HIV seroconversions were recorded during 54 845 person-years of follow-up. For each 
increase of ten percentage points in opposite-sex household antiretroviral therapy coverage, the HIV acquisition 
hazard was reduced by 6% (95% CI 2–9), after controlling for other factors. This eﬀ ect size translates into large 
reductions in HIV acquisition hazards when household antiretroviral therapy coverage is substantially increased. For 
example, an increase of 50 percentage points in household antiretroviral therapy coverage (eg, from 20% to 70%) 
reduced the hazard of HIV acquisition by 26% (95% CI 9–39).
Interpretation Our ﬁ ndings provide further evidence that antiretroviral therapy signiﬁ cantly reduces the risk of 
onward transmission of HIV in a real-world setting in sub-Saharan Africa. Awareness that antiretroviral therapy can 
prevent transmission to coresident sexual partners could be a powerful motivator for HIV testing and antiretroviral 
treatment uptake, retention, and adherence.
Funding Wellcome Trust and National Institute of Child Health and Human Development (US National Institutes 
of Health).
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Introduction
Early initiation of antiretroviral therapy can substantially 
improve the health and survival outcomes of HIV-infected 
patients.1 Over the past decade, several studies have shown 
that antiretroviral therapy can reduce the transmission of 
HIV from an infected to an uninfected sexual partner.2–4 
The strongest evidence for the preventive eﬀ ect of 
antiretroviral therapy has come from studies of HIV-
serodiscordant couples in stable sexual relationships.3 In 
2011, investigators of the HPTN 052 trial,5 now regarded as 
the landmark HIV treatment-as-prevention study, reported 
that early antiretroviral therapy reduced HIV transmission 
by 96% in HIV-serodiscordant couples who had disclosed 
their HIV status to each other. This result conﬁ rmed the 
ﬁ ndings of two earlier observational studies (reported in 
20066 and 20107), which showed that antiretroviral therapy 
was associated with a 98%6 and a 92%7 reduction in HIV 
incidence in serodiscordant heterosexual couples.
More recently, investigators of a prospective cohort study8 
reported a 66% fall in the rate of new HIV infections among 
married serodiscordant couples receiving antiretroviral 
therapy. These impressive results have established 
treatment as prevention as an eﬀ ective strategy to reduce 
the spread of HIV.
9–11
 Attention is now being focused on 
whether ﬁ ndings based on the study of serodiscordant 
couples can be generalised to the wider population.
12
A few ecological studies have shown increased uptake of 
antiretroviral therapy to be associated with a reduction in 
the number of new HIV diagnoses for a particular group, 
community, or administrative region over time.
13–15
 
However, such studies typically make use of aggregated 
outcomes and are therefore unable to assess the preventive 
eﬀ ect of antiretroviral therapy for individuals.
16
 In a 
previous study,17 we reported the time to seroconversion 
for 16 667 HIV-uninfected individuals on the basis of 
antiretroviral therapy coverage in the local community. 
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We deﬁ ned antiretroviral therapy coverage as the pro-
portion of all HIV-infected people on antiretroviral therapy 
irrespective of CD4 count or disease stage. After 
controlling for a wide range of potential confounders, we 
showed that an individual living in a community with 
30% antiretroviral therapy coverage was 38% less likely to 
acquire HIV than an individual living in a community 
with less than 10% coverage. This result provided power-
ful evidence for the community-level eﬀ ectiveness of 
treatment as prevention. However, no previous study has 
assessed the preventive eﬀ ect of antiretroviral therapy at 
the household level.
Here, we aimed to quantify the household-level 
preventive eﬀ ect of a public-sector HIV treatment and 
care programme based in a rural South African 
community with poor knowledge and disclosure of HIV 
status, frequent migration, late marriage, and multiple 
partnerships. Speciﬁ cally, we used information about the 
HIV serostatus and antiretroviral therapy status of 
household residents to assess whether antiretroviral 
therapy is associated with a reduction in HIV acquisition 
risk.
Methods
 Study population
In this prospective cohort study, we linked patient records 
from a public-sector HIV treatment programme with 
population-based HIV surveillance data collected between 
2004 and 2012 by the Africa Centre for Health and 
Population Studies. The population-based surveillance 
system at the Africa Centre was designed to capture the 
complex and dynamic demographic reality of the 
uMkanyakude district in the KwaZulu-Natal province of 
South Africa. The study area is roughly 440 km² in size 
with a resident population of 75 000 people and a total 
(resident and non-resident) population of 87 000 people. 
The area is generally poor and typical of a rural South 
African population, with scattered, informal, periurban 
settlements and a principal urban township.18
Historically, partnership stability in the study area has 
been profoundly aﬀ ected by frequent and long-term 
migration—the result of apartheid-era policies that sought 
to regulate the rural supply of African labourers into 
urban centres and prevent their spouses or families from 
joining them.19,20 Furthermore, marital rates (an important 
indicator of partnership stability) are low in the study area; 
in 2006, less than 20% of women and 10% of men aged 
35 years or younger had ever been married.21 Polygamous 
marriages constituted 12% of all marriages in women and 
14% in men.21 Men marry fairly late in life (median age 
34 years),22 because they typically need to save substantial 
proportions of their incomes for several years to be able to 
aﬀ ord the Zulu bridewealth payment. Before marriage, 
many men will have had several casual sexual 
relationships, thereby increasing the risk of HIV 
infection.21,23 Among sexually active men in our study area, 
29% reported having had two or more concurrent partners 
between 2004 and 2009. The mean number of reported 
lifetime sexual partners in the community was six.17,24
The overall HIV incidence in the study area between 
2004 and 2010 was 2⋅6 new infections per 100 person-years 
(95% CI 2⋅5–2⋅8).25 Incidence peaked at 6⋅6 per 100 person-
years in women aged 24 years, and at 4⋅1 per 100 person-
years in men aged 29 years.25 HIV prevalence for people 
aged 15–49 years has increased steadily from 22% in 2004 
to 29% in 2011.26 Antiretroviral therapy was made available 
to patients with CD4 counts less than 200 cells per μL 
through public-sector primary health-care clinics in 
September, 2004. Treatment eligibility was extended to 
patients with CD4 counts of less than 350 cells per μL for 
pregnant women and patients with active tuberculosis in 
April, 2010, and then for all adult patients in August, 2011.27 
Antiretroviral therapy coverage of all HIV-infected people 
in the study area rose from 0% in 2004 to 31% in 2011.26
The Africa Centre collects data for individuals who are 
members of family units or households in the study area. 
A household is deﬁ ned as a building or group of 
buildings belonging to a single owner and used by 
residents for the purposes of living.28 The average size of 
a household is seven resident members.29 Roughly 
21 500 households have been included in the Africa 
Centre’s household surveillance since 2000. Household 
response rates are typically greater than 95%, and 
information is collected for both resident and non-
resident members. Individual HIV testing has taken 
place within the household surveillance annually since 
2003. Eligible participants aged 15 years and older are 
interviewed in private by trained ﬁ eldworkers, who also 
extract blood by ﬁ nger prick for HIV testing. Overall, 
about 80% of all individuals in the study area consent to 
provide a blood sample for anonymous HIV testing.18 
Antiretroviral therapy is distributed through the HIV 
treatment and care programme by nurses and treatment 
counsellors, and records of patients’ antiretroviral 
therapy status are updated and maintained in the 
antiretroviral therapy evaluation and monitoring system 
(ARTemis) database. The Africa Centre surveillance and 
HIV treatment programme are described in greater 
detail elsewhere.18,29,30
Procedures
The outcome measure for our study is the time to 
seroconversion for a repeat-tester. We deﬁ ne a repeat-tester 
as an individual aged 15–50 years who has had more than 
one HIV test, was HIV-uninfected at the ﬁ rst test, and was 
a resident member of at least one household in the 
surveillance area between Jan 1, 2004, and Dec 31, 2012. 
The repeat-testers, who are at risk of HIV infection, are a 
subset of the total resident population under surveillance. 
To obtain the date of seroconversion, we randomly selected 
a timepoint between a repeat-tester’s latest HIV-uninfected 
and earliest HIV-infected test date. We right-censored 
repeat-testers who were HIV-uninfected at their most 
recent test.
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The household surveillance captures the complexity of a 
repeat-tester’s living arrangements through exposure 
episodes. A single exposure episode begins on the ﬁ rst 
day of the calendar year, or with the start of a new 
household residency, and ends on the last day of the 
calendar year, or with the migration of the repeat-tester to 
a diﬀ erent household within or outside the surveillance 
area. We used exposure episodes to measure the number 
of days spent by a repeat-tester in a single, distinct 
household within a calendar year, and to determine the 
coresident characteristics of the household for the 
corresponding exposure episode. Changes in household 
residencies within the surveillance area were captured 
with each new exposure episode. Thus, by deﬁ nition, a 
repeat-tester cannot be a resident of two diﬀ erent 
households at the same point in time.
To investigate the time to HIV seroconversion for 
varying household levels of antiretroviral therapy 
coverage and HIV prevalence, we linked the data from 
7657 adults living in the study area and enrolled in the 
local HIV treatment and care programme—who 
successfully started antiretroviral therapy and had an 
active follow-up status—with the data for the same 
individuals in the surveillance database. We used the 
linked records to determine whether a coresident was 
HIV-infected and not on antiretroviral therapy, HIV-
infected and on antiretroviral therapy, or HIV-uninfected 
at any speciﬁ c timepoint. We then used this information 
to construct measures of HIV prevalence and 
antiretroviral therapy coverage for the corresponding 
household. We deﬁ ned HIV prevalence as the proportion 
of coresidents who are HIV-infected, and antiretroviral 
therapy coverage as the proportion of HIV-infected 
coresidents who are on antiretroviral therapy. HIV 
prevalence and antiretroviral therapy coverage were 
coded in units of ten percentage points on a scale of 
0–100%. Because of the predominantly heterosexual 
transmission of HIV in our study area,17 we stratiﬁ ed 
household HIV prevalence and antiretroviral therapy 
coverage by sex, and used the opposite-sex antiretroviral 
therapy coverage as our main exposure variable.
We used the household as a proxy for coresident 
partners of the repeat-tester—ie, we did not speciﬁ cally 
identify whether the repeat-tester is in a sexual 
relationship with one or more opposite-sex coresidents 
for an exposure episode. We excluded coresident 
members younger than 15 years and those with an age 
diﬀ erence of 15 years or more from the repeat-tester to 
exclude speciﬁ c types of family members—grandparents, 
parents, children, and grandchildren—from being 
counted as possible sexual partners in the household.
To ensure suﬃ  cient exposure to HIV-infected 
coresidents (who are either on antiretroviral therapy or 
not), we excluded from our analysis repeat-testers who 
spend more than 50% of exposure time outside the 
surveillance area. We also excluded repeat-testers who 
lived alone, because these individuals were not eligible 
for the main exposure of interest (antiretroviral therapy 
coverage among opposite-sex household coresidents). 
We used detailed surveillance information about 
coresident deaths, migrations out of the surveillance 
area, and loss to follow-up to update the respective 
numerator or denominator of the household anti-
retroviral therapy coverage and HIV prevalence measures 
for each exposure episode for each repeat-tester.
Ethics approval for data collection, linkage, and use was 
obtained from the biomedical and ethics committee of the 
University of KwaZulu-Natal (Durban, South Africa).
Statistical analysis
We used a Cox proportional-hazards model to obtain an 
estimate for a repeat-tester’s hazard of HIV sero-
conversion conditional on household opposite-sex 
antiretroviral therapy coverage, controlling for household 
opposite-sex HIV prevalence, sex and age (in 5-year sex-
age strata), knowledge of own HIV status (yes, no, or 
refused), having heard about antiretroviral therapy (yes, 
no, or refused), area of residence (rural, peri-urban, or 
urban), household wealth (by quintile, based on an assets 
index generated in principal component analysis), 
number of opposite-sex household residents, and 
number of household residency changes by the repeat-
tester (none, one, or two or more). All variables apart 
from the repeat-tester’s sex were time-varying. We report 
95% CIs based on SEs that have been adjusted for 
clustering at the household level. The main results are 
reported for a regression model based on data for 
opposite-sex coresidents only (opposite-sex model).
Even after controlling for the independent variables in 
the opposite-sex regression model, the relation between 
HIV seroconversion hazard and household opposite-sex 
antiretroviral therapy coverage could be confounded by a 
range of unobserved factors, such as conscientiousness 
of individual household members, attitudes towards 
risk, and attitudes towards health. Although we cannot 
include these factors in the regression because we do not 
have data for them, we can control for their confounding 
eﬀ ects by adding same-sex antiretroviral therapy 
coverage and same-sex HIV prevalence. A household’s 
same-sex antiretroviral therapy coverage will depend on 
many of the same unobserved factors, such as household 
members’ conscientiousness and attitudes, that are also 
likely to aﬀ ect a household’s opposite-sex antiretroviral 
therapy coverage. Thus we also report the results after 
adding household same-sex antiretroviral therapy 
coverage and same-sex HIV prevalence to the regression 
(full model).
We also did an alternative analysis in which household 
antiretroviral therapy coverage and HIV prevalence were 
treated as binary variables (none vs one or more HIV-
infected coresidents on antiretroviral therapy, and none 
vs one or more HIV-infected coresidents) rather than in 
units of ten percentage points.
All statistical analyses were done with Stata (version 12.1).
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Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
14 505 repeat-testers met our inclusion and exclusion 
criteria of whom 8546 (59%) were women. 2037 HIV 
seroconversions were recorded over 54 845 person-years of 
follow-up time during the 2004–12 period. The median 
follow-up time per repeat-tester was 3⋅2 years 
(IQR 1⋅8–5⋅5), with a maximum of 10⋅2 years. The 
unadjusted HIV incidence over the study period 
was 3⋅7 new infections per 100 person-years (95% CI 
3⋅6–3⋅9). Incidence was highest in the 20–24 years age 
group for women and in the 25–29 years age group for 
men (table 1). Unadjusted HIV incidence remained stable 
from 2004 to 2008 and then fell from 3⋅9 per 100 person-
years in 2008 to 2⋅8 per 100 person-years in 2012 (table 1).
An average of 4102 (range 1131–5119) households per 
year were included in the analysis during the study period. 
About 10% of the repeat-testers changed household 
residencies one or more times during the study period. 
Repeat-testers were exposed to a mean of 1⋅2 (SD 0⋅5) 
diﬀ erent antiretroviral therapy coverage levels (coded in 
units of ten percentage points).
For every increase of ten percentage points in opposite-
sex household antiretroviral therapy coverage the hazard 
of HIV acquisition was reduced by 6% (95% CI 2–9), 
after controlling for household HIV prevalence and the 
other independent variables (table 2). Table 3 shows the 
adjusted HIV acquisition hazards for diﬀ erent percentage 
point increases in household antiretroviral therapy 
coverage. For example, an increase of 50 percentage 
points in opposite-sex household antiretroviral therapy 
coverage (eg, an increase from 0% to 50%, from 10% to 
60%, or from 20% to 70%), was associated with a 26% 
(95% CI 9–39) reduction in the hazard of HIV acquisition.
The full model included measures of same-sex 
antiretroviral therapy coverage and same-sex HIV 
prevalence. The point estimate for the change in hazard 
of HIV acquisition for an increase of ten percentage 
points in household antiretroviral therapy coverage was 
the same as the one in the opposite-sex model (table 2). 
The adjusted hazard ratio (HR) for household same-sex 
HIV prevalence was not signiﬁ cant (table 2). Results for 
univariate analyses are shown in the appendix.
In the alternative analysis (in which we coded household 
antiretroviral therapy coverage and HIV prevalence as 
binary variables), the hazard of HIV acquisition for an 
individual living in a household with at least one HIV-
infected coresident on antiretroviral therapy was 24% less 
than for an individual living in a household in which none 
of the HIV-infected coresidents were on antiretroviral 
therapy (adjusted HR 0⋅76, 95% CI 0⋅60–0⋅95, p=0⋅017).
Person-
years
Number of 
HIV serocon-
versions
HIV incidence*
(95% CI)
Calendar year
2004 5552 208 3·75 (3·27–4·29)
2005 7060 269 3·81 (3·38–4·29)
2006 7575 321 4·24 (3·80–4·73)
2007 7347 268 3·65 (3·24–4·11)
2008 7102 275 3·87 (3·44–4·36)
2009 6389 237 3·71 (3·27–4·21)
2010 5724 203 3·55 (3·09–4·07)
2011 4858 164 3·38 (2·90–3·93)
2012 3239 92 2·84 (2·32–3·48)
Age-sex stratum
Women aged 15–19 years 9179 451 4·91 (4·48–5·39)
Women aged 20–24 years 7478 583 7·80 (7·19–8·46)
Women aged 25–29 years 3140 204 6·50 (5·66–7·45)
Women aged 30–34 years 2271 96 4·23 (3·46–5·16)
Women aged 35–39 years 2795 70 2·50 (1·98–3·17)
Women aged 40–44 years 3513 77 2·19 (1·75–2·74)
Women aged ≥45 years 5349 73 1·36 (1·09–1·72)
Men aged 15–19 years 8373 75 0·90 (0·71–1·12)
Men aged 20–24 years 5848 192 3·28 (2·85–3·78)
Men aged 25–29 years 2082 97 4·66 (3·82–5·68)
Men aged 30–34 years 1171 38 3·25 (2·36–4·46)
Men aged 35–39 years 1039 31 2·98 (2·10–4·24)
Men aged 40–44 years 1076 24 2·23 (1·50–3·33)
Men aged ≥45 years 1531 26 1·70 (1·16–2·49)
Knows HIV status
Yes 36 596 1372 3·75 (3·56–3·95)
No 4331 131 3·02 (2·55–3·59)
Refused 13 918 534 3·84 (3·52–4·18)
Has heard about antiretroviral therapy
Yes 23 614 880 3·73 (3·49–3·98)
No 4452 134 3·01 (2·54–3·56)
Refused 26 778 1023 3·82 (3·59–4·06)
Area of residence
Peri-urban 16 597 724 4·36 (4·06–4·69)
Rural 36 613 1248 3·41 (3·22–3·60)
Urban 1634 65 3·98 (3·12–5·07)
Household wealth quintile
Poorest 11 117 368 3·31 (2·99–3·67)
Second poorest 12 251 437 3·57 (3·25–3·92)
Third poorest 11 916 467 3·92 (3·58–4·29)
Fourth poorest 10 981 464 4·23 (3·86–4·63)
Wealthiest 8580 301 3·51 (3·13–3·93)
Changes of household residencies
None 50 481 1828 3·62 (3·46–3·79)
One 3642 169 4·64 (3·99–5·39)
Two or more 722 40 5·54 (4·06–7·55)
*New infections per 100 person-years.
Table  1: Incidence of HIV-1 seroconversion by sociodemographic variables, 
2004–12
See Online for appendix
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Opposite-sex model Full model
Adjusted hazard ratio (95% CI) p value Adjusted hazard ratio (95% CI) p value
Opposite-sex antiretroviral therapy coverage* 0·94 (0·91–0·98) 0·0036 0·94 (0·91–0·98) 0·0034
Opposite-sex HIV prevalence† 1·05 (1·03–1·07) <0·0001 1·05 (1·03–1·07) <0·0001
Number of opposite-sex coresidents‡ 0·98 (0·96–1·02) 0·4072 0·98 (0·95–1·02) 0·3292
Knows HIV status
Yes (reference) 1·00 ·· 1·00 ··
No 1·11 (0·99–1·25) 0·0705 1·11 (0·99–1·25) 0·0695
Refused 1·30 (0·60–2·80) 0·5004 1·30 (0·60–2·79) 0·5027
Has heard about antiretroviral therapy
Yes (reference) 1·00 ·· 1·00 ··
No 0·98 (0·88–1·10) 0·7476 0·98 (0·88–1·10) 0·7846
Refused 0·70 (0·33–1·49) 0·3592 0·70 (0·33–1·50) 0·3616
Age-sex stratum
Men aged 15–19 years (reference) 1·00 ·· 1·00 ··
Men aged 20–24 years 3·76 (2·87–4·93) <0·0001 3·77 (2·87–4·94) <0·0001
Men aged 25–29 years 5·36 (3·95–7·26) <0·0001 5·36 (3·95–7·27) <0·0001
Men aged 30–34 years 3·72 (2·47–5·59) <0·0001 3·70 (2·46–5·56) <0·0001
Men aged 35–39 years 3·38 (2·23–5·13) <0·0001 3·37 (2·22–5·11) <0·0001
Men aged 40–44 years 2·56 (1·62–4·06) <0·0001 2·55 (1·61–4·05) <0·0001
Men aged ≥45 years 2·01 (1·28–3·15) 0·0023 2·00 (1·28–3·14) 0·0024
Women aged 15–19 years 5·75 (4·52–7·32) <0·0001 5·75 (4·51–7·32) <0·0001
Women aged 20–24 years 9·59 (7·52–12·23) <0·0001 9·58 (7·50–12·23) <0·0001
Women aged 25–29 years 8·04 (6·14–10·52) <0·0001 8·03 (6·13–10·52) <0·0001
Women aged 30–34 years 5·11 (3·78–6·90) <0·0001 5·10 (3·77–6·90) <0·0001
Women aged 35–39 years 3·03 (2·18–4·22) <0·0001 3·03 (2·17–4·22) <0·0001
Women aged 40–44 years 2·63 (1·90–3·65) <0·0001 2·63 (1·90–3·65) <0·0001
Women aged ≥45 years 1·68 (1·21–2·33) 0·0018 1·68 (1·21–2·33) 0·0018
Area of residence
Rural (reference) 1·00 ·· 1·00 ··
Peri-urban 1·29 (1·16–1·44) <0·0001 1·29 (1·16–1·43) <0·0001
Urban 1·27 (0·97–1·67) 0·0861 1·27 (0·97–1·67) 0·0866
Household wealth quintile
Poorest (reference) 1·00 ·· 1·00 ··
Second poorest 1·04 (0·90–1·20) 0·6883 1·04 (0·90–1·20) 0·5874
Third poorest 1·06 (0·92–1·23) 0·4065 1·06 (0·92–1·23) 0·4148
Fourth poorest 1·14 (0·98–1·32) 0·0848 1·14 (0·98–1·32) 0·0857
Wealthiest 0·91 (0·77–1·08) 0·2856 0·91 (0·77–1·08) 0·2843
Changes of household residencies
None (reference) 1·00 ·· 1·00 ··
One 1·15 (0·97–1·35) 0·1075 1·14 (0·97–1·35) 0·1067
Two or more 1·26 (0·92–1·73) 0·1437 1·26 (0·92–1·73) 0·1442
Same-sex antiretroviral therapy coverage* ·· ·· 1·03 (0·98–1·08) 0·2974
Same-sex HIV prevalence† ·· ·· 1·00 (0·96–1·05) 0·8380
Number of seroconversions 2037 ·· 2037 ··
Number of at-risk individuals 14 505 ·· 14 505 ··
95% CIs are based on SEs that have been adjusted for clustering at the household level. *Adjusted hazard ratio represents the change in HIV seroconversion hazard for any 
increase of ten percentage points in household antiretroviral therapy coverage, controlling for the other independent variables in the regression model. †Adjusted hazard 
ratio represents the change in HIV seroconversion hazard for any increase of ten percentage points in household HIV prevalence, controlling for the other independent 
variables in the regression model. ‡Adjusted hazard ratio represents the change in HIV seroconversion hazard for an increase in household size by one opposite-sex member, 
controlling for the other independent variables in the regression model.
Table 2: Results of multivariable analysis for the eﬀ ect of an increase in opposite-sex household antiretroviral therapy coverage on HIV seroconversion hazard
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Discussion
Our study has shown that for each increase of ten 
percentage points in opposite-sex household antiretroviral 
therapy coverage, the HIV acquisition hazard was reduced 
by 6% (95% CI 2–9), after controlling for other factors. 
This eﬀ ect size translates into large reductions in HIV 
acquisition hazards when household antiretroviral therapy 
coverage is substantially increased—eg, an increase of 50 
percentage points in household antiretroviral therapy 
coverage (eg, from 20% to 70%) reduced the hazard of 
HIV acquisition by 26% (95% CI 9–39). Importantly, our 
results show that the preventive eﬀ ectiveness of 
antiretroviral therapy can persist in social contexts in 
which stable sexual partnerships are diﬃ  cult to identify, 
occur late in life, or are not the norm. Our study provides 
the ﬁ rst real-world evidence for the preventive eﬀ ectiveness 
of antiretroviral therapy within the household setting 
(panel).
Our study had several limitations. Although we used 
linked clinical and population-based cohort data, we 
cannot completely rule out the eﬀ ect of unobserved 
confounding on our results. A better approach to 
address confounding would be a randomised control 
trial, but this strategy would not be possible at the 
household level for ethical and methodological reasons. 
However, by controlling for same-sex antiretroviral 
therapy coverage in the household, we do account for 
unobserved factors at the household level that aﬀ ect 
both opposite-sex and same-sex coverage and could 
confound the observed relation between opposite-sex 
coverage and HIV acquisition. Such factors include the 
conscientiousness of household members, attitudes 
towards risk, and attitudes towards health, which are 
highly plausible confounders in this study, but diﬃ  cult 
to measure directly.
Our inability to individually link HIV-uninfected 
individuals to sexual partners outside the household, 
along with the possible migration of sexual partners 
outside of the study area, makes accurate measurement 
of the preventive eﬀ ectiveness of antiretroviral therapy 
diﬃ  cult. Since a subset of HIV-infected individuals (who 
might or might not be on antiretroviral therapy) in our 
cohort did not reside in the same household as their 
uninfected sexual partner and were therefore excluded 
from the analysis, our ﬁ nding should be regarded as a 
minimum estimate of the preventive eﬀ ectiveness of 
antiretroviral therapy.
In our study, we included a coresident member in the 
measure of household antiretroviral therapy coverage if 
his or her date of antiretroviral therapy initiation was 
before a residency in a household and if his or her clinic 
follow-up status was still active during the residency 
period. We therefore could have further underestimated 
the preventive beneﬁ t of antiretroviral therapy since we 
did not account for patients failing antiretroviral 
therapy.
Important strengths of our study include the use of one 
of the world’s largest HIV incidence cohorts and the 
ability of our data and study design to capture the 
changing demographic conditions of an HIV-uninfected 
individual’s living arrangements over time. In this 
respect, our study is unique because it uses information 
about HIV serostatus and antiretroviral therapy status 
among coresident household members to test the 
treatment-as-prevention hypothesis in a real-world setting 
in sub-Saharan Africa. Awareness that antiretroviral 
Panel: Research in context
Systematic review
We did not do a systematic review of the scientiﬁ c literature, but referred to three 
previously published systematic reviews2–4 (synthesising evidence from a total of one 
randomised controlled trial and nine observational studies), which showed that 
antiretroviral therapy substantially reduced or prevented HIV transmission among 
serodiscordant couples. The authors of two reviews12,16 concluded that ecological studies 
have methodological limitations, and that the population-level preventive beneﬁ t of 
antiretroviral therapy has yet to be proven. Results of one study25 showed that high 
antiretroviral therapy coverage was associated with a reduction in individual risk of HIV 
acquisition at the community level. We searched PubMed for reports published in English 
between Jan 1, 2004, and Dec 1, 2013, using the search terms “antiretroviral therapy”, 
“prevention”, and “household”. We did not identify any studies that assessed the 
association between risk of HIV acquisition at the individual level and household 
antiretroviral therapy coverage.
Interpretation
Our study provides further evidence that treatment with antiretroviral therapy 
signiﬁ cantly reduces the risk of onward transmission of HIV in a real-world setting in 
sub-Saharan Africa. Public promotion of the preventive beneﬁ ts of antiretroviral therapy 
could help to motivate individuals to learn their HIV status and seek treatment. 
Adherence to antiretroviral therapy is more likely to be sustained if HIV-infected 
individuals are aware that the therapy will protect their sexual partners from acquiring the 
infection. Similarly, the knowledge that antiretroviral therapy can provide protection 
from HIV acquisition could motivate HIV-uninfected individuals to persuade their 
infected coresident partners to initiate antiretroviral therapy, improving the long-term 
use of life-saving drugs within the household. 
Adjusted hazard ratio (95% CI)*
10 percentage points 0·94 (0·91–0·98)
20 percentage points 0·89 (0·82–0·96)
30 percentage points 0·84 (0·74–0·94)
40 percentage points 0·79 (0·67–0·92)
50 percentage points 0·74 (0·61–0·91)
60 percentage points 0·70 (0·55–0·89)
70 percentage points 0·66 (0·50–0·87)
80 percentage points 0·62 (0·45–0·85)
90 percentage points 0·58 (0·41–0·84)
100 percentage points 0·55 (0·37–0·82)
*Data are adjusted for opposite-sex household HIV prevalence and the other 
independent variables included in the opposite-sex model; the eﬀ ect size for each 
percentage-point increase will be the same irrespective of the baseline coverage.
Table 3: Eﬀ ect of percentage-point increases in opposite-sex household 
antiretroviral therapy coverage on HIV acquisition hazard
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therapy can prevent transmission to coresident sexual 
partners could motivate individuals to disclose their HIV 
status and to seek and adhere to treatment, improving the 
long-term use of live-saving antiretroviral therapy.
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